Evidence map›Paper›PMID 38138294›Full record

ArticleMedicina (Kaunas, Lithuania)2023

Diagnostic and Prognostic Value of IL-10, FABP2 and LPS Levels in HCC Patients.

Egidijus Morkunas, Evelina Vaitkeviciute, Greta Varkalaite, Vidas Pilvinis, Jurgita Skieceviciene, Juozas Kupcinskas

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Egidijus MorkunasDepartment of Gastroenterology, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.
Evelina VaitkeviciuteInstitute for Digestive Research, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.
Greta VarkalaiteInstitute for Digestive Research, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.
Vidas PilvinisDepartment of Anesthesiology, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.
Jurgita SkiecevicieneInstitute for Digestive Research, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.ORCID 0000-0002-4893-6612
Juozas KupcinskasDepartment of Gastroenterology, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.ORCID 0000-0002-8760-7416
Lithuanian University of Health Sciences · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) still lacks valuable diagnostic and prognostic tools. This study aimed to investigate the potential diagnostic and prognostic value of baseline interleukin (IL)-10, fatty acid-binding protein 2 (FABP2) and lipopolysaccharide (LPS) levels in patients with HCC. Serum levels of IL-10, FABP2 and LPS in 47 newly diagnosed HCC patients and 50 healthy individuals were estimated and compared. The best cut-off points for baseline IL-10, FABP2 and LPS levels predicting overall survival (OS) were evaluated. Both levels of FABP2 and IL-10 were significantly higher in HCC patients vs. control group (median 2095 vs. 1772 pg/mL,

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorFatty Acid-Binding ProteinsHumansInterleukin-10LipopolysaccharidesPrognosisBiomarkers, TumorFABP2 protein, humanFatty Acid-Binding ProteinsInterleukin-10LipopolysaccharidesbiomarkerFABP2HCChepatocellular carcinomaIL-10LPSprognosis

Identifiers

PMID38138294
PMCPMC10744942
OpenAlexW4389924657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.